Immunological mechanisms of allergen-specific immunotherapy

Nature Reviews Immunology

Volumn 6, Issue 10, 2006, Pages 761-771

  Larché, Mark ^a,b   Akdis, Cezmi A ^c   Valenta, Rudolf ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; BEE VENOM; CHITOSAN; DNA VACCINE; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; PLASMID DNA; RECOMBINANT PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC REACTION; ALLERGIC RHINITIS; ALLERGY; ANTIGEN SPECIFICITY; ASTHMA; B LYMPHOCYTE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; URTICARIA; VACCINATION;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; LYMPHOCYTES;

EID: 33749016485     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1934     Document Type: Review

References (145)

1. von Pirquet, C. Allergie. Munch. Med. Wochenschr. 53, 1457 (1906) (in German).
2. Floistrup, H. et al. Allergic disease and sensitization in Steiner school children. J. Allergy Clin. Immunol. 117, 59-66 (2006).
3. Valenta, R. et al. Immunotherapy of allergic disease. Adv. Immunol. 82, 105-153 (2004).
4. Prausnitz, C. & Küstner, J. Studien uber die Ueberempfindlichkeit. Zentralbl. Bakteriol. [Orig.] 86, 160-169 (1921) (in German).
5. Ishizaka, K., Ishizaka, T. & Hornbrook, M. M. Physicochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J. Immunol. 97, 75-85 (1966).
6. Johansson, S. G. O. & Bennich, H. Immunoglobulin studies of atypical (myeloma) immunoglobulin. Immunology 13, 381-394 (1967).
7. Mudde, G. C., Hansel, T. T., von Reijsen, F. C., Osterhoff, B. F. & Bruijnzeel-Koomen, C. A. IgE: an immunoglobulin specialized in antigen capture? Immunol. Today 11, 440-443 (1990).
8. Fahy, J. V. et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am. J. Respir. Crit. Care Med. 160, 1023-1027 (1999).
9. Ong, Y. E. et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J. Allergy Clin. Immunol. 116, 558-564 (2005).
10. Kay, A. B. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344, 30-37 (2001).
11. Kay, A. B. Allergy and allergic diseases. Second of two parts. N. Engl. J. Med. 344, 109-113 (2001).
12. Akdis, C. A., Blaser, K. & Akdis, M. Apoptosis in tissue inflammation and allergic disease. Curr. Opin. Immunol. 16, 717-723 (2004).
13. Noon, L. Prophylactic inoculation against hay fever. Lancet i, 1572-1573 (1911).
14. Durham, S. R. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468-475 (1999). Shows the long-term clinical efficacy of SIT, even following withdrawal of treatment.
15. Golden, D. B., Kagey-Sobotka, A., Norman, P. S., Hamilton, R. G. & Lichtenstein, L. M. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N. Engl. J. Med. 351, 668-674 (2004).
16. Pajno, G. B., Barberio, G., De Luca, F., Morabito, L. & Parmiani, S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31, 1392-1397 (2001).
17. Moller, C. et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109, 251-256 (2002). Shows that SIT prevents the progression of allergic rhinitis to asthma.
18. Walker, S. M., Pajno, G. B., Lima, M. T., Wilson, D. R. & Durham, S. R. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J. Allergy Clin. Immunol. 107, 87-93 (2001).
19. Lichtenstein, L. M., Ishizaka, K., Norman, P. S., Sobotka, A. K. & Hill, B. M. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J. Clin. Invest. 52, 472-482 (1973).
20. Warner, J. O., Price, J. F., Soothill, J. F. & Hey, E. N. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2, 912-915 (1978).
21. Varney, V. A. et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 92, 644-651 (1993).
22. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J. Allergy Clin. Immunol. 97, 1356-1365 (1996).
23. Freeman, J. & Noon, L. Further observations on the treatment of hayfever by hypodermic inoculations of pollen vaccine. Lancet ii, 814-817 (1911).
24. Zoss, A. R., Koch, C. A. & Hirose, R. S. Alum-ragweed precipitate: preparation and clinical investigation; preliminary report. J. Allergy 8, 329-335 (1937).
25. Attallah, N. A. & Sehon, A. H. Isolation of haptenic material from ragweed pollen. Immunochemistry 6, 609-619 (1969).
26. Malley, A. & Perlman, F. Induction of both reaginic and blocking antibodies with a low molecular weight fraction of timothy pollen extract. J. Allergy 43, 59-64 (1969).
27. Marsh, D. G., Lichtenstein, L. M. & Campbell, D. H. Studies on 'allergoids' prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 18, 705-722 (1970).
28. Chua, K. Y. et al. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J. Exp. Med. 167, 175-182 (1988). Describes the cloning of the first allergen gene.
29. Larché, M. & Wraith, D. C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Med. 11, S69-S76 (2005).
30. Niederberger, V. et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14677-14682 (2004). Describes the first clinical trial of genetically engineered recombinant allergens.
31. Jutel, M. et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116, 608-613 (2005). Describes the first clinical trial of 'native' recombinant allergens.
32. Tulic, M. K. et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113, 235-241 (2004). Describes the use of DNA-allergen conjugates for the treatment of allergic rhinitis.
33. Wilson, D. R. et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin. Exp. Allergy 31, 1705-1713 (2001).
34. Rak, S., Heinrich, C., Jacobsen, L., Scheynius, A. & Venge, P. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J. Allergy Clin. Immunol. 108, 921-928 (2001).
35. Durham, S. R. et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin. Exp. Allergy 29, 1490-1496 (1999).
36. Shim, J. Y., Kim, B. S., Cho, S. H., Min, K. U. & Hong, S. J. Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin. Exp. Allergy 33, 52-57 (2003).
37. Vermaelen, K. Y., Carro-Muino, I., Lambrecht, B. N. & Pauwels, R. A. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J. Exp. Med. 193, 51-60 (2001).
38. Lambrecht, B. N., Pauwels, R. A. & Fazekas De St Groth, B. Induction of rapid T cell activation, division, and recirculation by intratracheal injection of dendritic cells in a TCR transgenic model. J. Immunol. 164, 2937-2946 (2000).
39. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213-1222 (2000).
40. Akbari, O., DeKruyff, R. H. & Umetsu, D. T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nature Immunol. 2, 725-731 (2001).
41. de Heer, H. J. et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J. Exp. Med. 200, 89-98 (2004).
42. Akdis, C. A., Blesken, T., Akdis, M., Wuthrich, B. & Blaser, K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 102, 98-106 (1998).
43. Nouri-Aria, K. T. et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172, 3252-3259 (2004).
44. Ebner, C. et al. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J. Immunol. 154, 1932-1940 (1995).
45. Mark, P. G., Segal, D. B., Dallaire, M. L. & Garman, R. D. Human T and B cell immune responses to Fel d 1 in cat-allergic and non-cat-allergic subjects. Clin. Exp. Allergy 26, 1316-1328 (1996).
46. 2-specific T cell clones from human allergic and non-allergic individuals: cytokine patterns change in response to the antigen concentration. Eur. J. Immunol. 22, 1357-1363 (1992).
47. Akdis, M. et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 199, 1567-1575 (2004). First report of the presence of allergen-specific regulatory T cells in healthy individuals.
48. Reg cells in individuals who suffer from allergies.
49. Jutel, M. et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33, 1205-1214 (2003).
50. + T cell population with regulatory activity. PLoS Med. 2, e78 (2005). First evidence that SIT with peptides induces antigen-specific regulatory T-cell responses.
51. + T cells from allergic individuals. J. Exp. Med. 178, 2123-2130 (1993).
52. H1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27, 1007-1015 (1997).
53. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98, 1676-1683 (1996). First article to show direct T-cell tolerance to T-cell epitopes derived from a major allergen and the recovery of the T-cell response using IL-2 and IL-15.
54. H1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 27, 1131-1139 (1997).
55. Nasser, S. M., Ying, S., Meng, Q., Kay, A. B. & Ewan, P. W. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur. J. Immunol. 31, 3704-3713 (2001).
56. + T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111, 1255-1261 (2003).
57. Akdis, C. A. & Blaser, K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 13, 603-609 (1999).
58. Tarzi, M. et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin. Exp. Allergy 36, 465-474 (2006).
59. Royer, B. et al. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin. Exp. Allergy 31, 694-704 (2001).
60. Schandene, L. et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J. Immunol. 152, 4368-4374 (1994).
61. Ohkawara, Y. et al. CD40 expression by human peripheral blood eosinophils. J. Clin. Invest. 97, 1761-1766 (1996).
62. Drachenberg, K. J., Wheeler, A. W., Stuebner, P. & Horak, F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56, 498-505 (2001).
63. Mothes, N. et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33, 1198-1208 (2003).
64. Muller, U. R. Bee venom allergy in beekeepers and their family members. Curr. Opin. Allergy Clin. Immunol. 5, 343-347 (2005).
65. Aalberse, R. C., van der Gaag, R. & van Leeuwen, J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J. Immunol.130, 722-726 (1983).
66. H2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 357, 752-756 (2001).
67. Cooke, R. A., Bernhard, J. H., Hebald, S. & Stull, A. Serological evidence of immunity with co-existing sensitisation in a hay fever type of human allergy. J. Exp. Med. 62, 733-750 (1935).
68. Loveless, M. H. Immunological studies of pollenosis. I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay fever patients. J. Immunol. 38, 25-50 (1940).
69. Lichtenstein, L. M., Holtzman, N. A. & Burnett, L. S. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J. Immunol. 101, 317-324 (1968).
70. Golden, D. B., Meyers, D. A., Kagey-Sobotka, A., Valentine, M. D. & Lichtenstein, L. M. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J. Allergy Clin. Immunol. 69, 489-493 (1982).
71. Muller, U., Helbling, A. & Bischof, M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 44, 412-418 (1989).
72. Djurup, R. & Malling, H. J. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin. Allergy 17, 459-468 (1987).
73. Visco, V. et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J. Immunol. 157, 956-962 (1996).
74. Denepoux, S. et al. Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett. 465, 39-46 (2000).
75. Flicker, S. et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG1 antibody. Eur. J. Immunol. 32, 2156-2162 (2002).
76. Reisinger, J. et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. 116, 347-354 (2005).
77. Gleich, G. J., Zimmermann, E. M., Henderson, L. L. & Yunginger, J. W. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J. Allergy Clin. Immunol. 70, 261-271 (1982).
78. + T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163, 2944-2952 (1999). First study to show that SIT-induced allergen-specific IgG reduces T-cell activation.
79. Achatz, G., Nitschke, L. & Lamers, M. C. Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. Science 276, 409-411 (1997).
80. Aalberse, R. C. & Schuurman, J. IgG4 breaking the rules. Immunology 105, 9-19 (2002).
81. Jeannin, P., Lecoanet, S., Delneste, Y., Gauchat, J. F. & Bonnefoy, J. Y. IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. 160, 3555-3561 (1998).
82. +) B cells to secrete IgG1 and IgG3. J. Exp. Med. 179, 757-762 (1994).
83. Kawano, Y., Noma, T. & Yata, J. Regulation of human IgG subclass production by cytokines. IFN-γ and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J. Immunol. 153, 4948-4958 (1994).
84. Valenta, R. The future of antigen-specific immunotherapy of allergy. Nature. Rev. Immunol. 2, 446-453 (2002).
85. Hiller, R. et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 16, 414-416 (2002). First paper to describe the use of allergen-microarray analysis for diagnosis of allergy.
86. Schmid-Grendelmeier, P. & Crameri, R. Recombinant allergens for skin testing. Int. Arch. Allergy Immunol. 125, 96-111 (2001).
87. Linhart, B. & Valenta, R. Molecular design of allergy vaccines. Curr. Opin. Immunol. 17, 646-655 (2005).
88. Vrtala, S. et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J. Immunol. 165, 6653-6659 (2000).
89. Bannon, G. A., Shin, D., Maleki, S., Kopper, R. & Burks, A. W. Tertiary structure and biophysical properties of a major peanut allergen, implications for the production of a hypoallergenic protein. Int. Arch. Allergy Immunol. 118, 315-316 (1999).
90. Buhot, C. et al. Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein Sci. 13, 2970-2978 (2004).
91. Okada, T., Swoboda, I., Bhalla, P. L., Toriyama, K. & Singh, M. B. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett. 434, 255-260 (1998).
92. Swoboda, I. et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur. J. Immunol. 32, 270-280 (2002).
93. Arquint, O. et al. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J. Allergy Clin. Immunol. 104, 1239-1243 (1999).
94. Stanley, J. S. et al. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch. Biochem. Biophys. 342, 244-253 (1997).
95. Drew, A. C. et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J. Immunol. 173, 5872-5879 (2004).
96. Bolhaar, S. T. et al. A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebo-controlled food challenge. Clin. Exp. Allergy 35, 1638-1644 (2005).
97. King, T. P. et al. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J. Immunol. 166, 6057-6065 (2001).
98. Linhart, B. et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. 115, 1010-1016 (2005).
99. Hirahara, K. et al. Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J. Allergy Clin. Immunol. 108, 94-100 (2001).
100. Gafvelin, G. et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int. Arch. Allergy Immunol. 138, 59-66 (2005).
101. Karamloo, F. et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur. J. Immunol. 35, 3268-3276 (2005).
102. Kussebi, F. et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115, 323-329 (2005).
103. Zhu, D. et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nature Med. 11, 446-449 (2005).
104. Norman, P. S. et al. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154, 1623-1628 (1996). First clinical trial to use allergen-derived T-cell-epitope-based peptides.
105. 2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101, 747-754 (1998).
106. Oldfield, W. L., Larché, M. & Kay, A. B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360, 47-53 (2002).
107. Fellrath, J. M. et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a Phase I trial. J. Allergy Clin. Immunol. 111, 854-861 (2003).
108. Haselden, B. M., Kay, A. B. & Larché, M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189, 1885-1894 (1999).
109. + T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy 35, 52-58 (2005).
110. Alexander, C., Tarzi, M., Larché, M. & Kay, A. B. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60, 1269-1274 (2005).
111. de Weck, A. L. & Schneider, C. H. Specific inhibition of allergic reactions to penicillin in man by a monovalent hapten. I. Experimental immunological and toxicologic studies. Int. Arch. Allergy Appl. Immunol. 42, 782-797 (1972).
112. Ball, T. et al. B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. 13, 1277-1290 (1999).
113. Focke, M. et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15, 2042-2044 (2001). Shows the usefulness of allergen-derived B-cell-epitope-based peptides for SIT.
114. Gajhede, M. et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nature Struct. Biol. 3, 1040-1045 (1996).
115. Westritschnig, K. et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J. Immunol. 172, 5684-5692 (2004).
116. Ganglberger, E. et al. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. FASEB J. 15, 2524-2526 (2001).
117. Suphioglu, C. et al. A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction. FEBS Lett. 502, 46-52 (2001).
118. Simons, F. E., Shikishima, Y., Van Nest, G., Eiden, J. J. & HayGlass, K. T. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113, 1144-1151 (2004).
119. Wilcock, L. K., Francis, J. N. & Durham, S. R. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin. Exp. Allergy 34, 1373-1378 (2004).
120. Gronlund, H. et al. Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107, 523-529 (2002).
121. Roth-Walter, F. et al. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 23, 2703-2710 (2005).
122. Bohle, B. et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol. 172, 6642-6648 (2004).
123. Akdis, C. A. et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur. J. Immunol. 33, 2717-2726 (2003).
124. H2-mediated IgE responses. Proc. Natl Acad. Sci. USA 102, 17525-17530 (2005).
125. Li, X. M. et al. Persistent protective effect of heat-killed Escherichia coli producing 'engineered,' recombinant peanut proteins in a murine model of peanut allergy. J. Allergy Clin. Immunol. 112, 159-167 (2003).
126. H1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl Acad. Sci. USA 93, 5141-5145 (1996).
127. Hsu, C. H. et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nature Med. 2, 540-544 (1996). References 126 and 127 were the first to propose the use of DNA vaccines for the treatment of allergy.
128. Roy, K., Mao, H. Q., Huang, S. K. & Leong, K. W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Med. 5, 387-391 (1999).
129. Slater, J. E., Paupore, E., Zhang, Y. T. & Colberg-Poley, A. M. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J. Allergy Clin. Immunol. 102, 469-475 (1998).
130. Weiss, R. et al. Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases. Curr. Drug Targets Inflamm. Allergy 4, 585-597 (2005).
131. Black, J. H. The oral administration of ragweed pollen. J. Allergy 10, 156-158 (1939).
132. Feinberg, S. M., Foran, F. L. & Lichtenstein, M. Oral pollen therapy in ragweed pollinosis. J. Am. Med. Assoc. 115, 23-39 (1940).
133. Cox, L. S. et al. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 117, 1021-1035 (2006).
134. Wilson, D. R., Lima, M. T. & Durham, S. R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60, 4-12 (2005).
135. Moingeon, P. et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61, 151-165 (2006).
136. Bahceciler, N. N. et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int. Arch. Allergy Immunol. 136, 287-294 (2005).
137. Rolinck-Werninghaus, C. et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int. Arch. Allergy Immunol. 136, 134-141 (2005).
138. Lima, M. T. et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin. Exp. Allergy 32, 507-514 (2002).
139. Pajno, G. B., Morabito, L., Barberio, G. & Parmiani, S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 55, 842-849 (2000).
140. Fanta, C. et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int. Arch. Allergy Immunol. 120, 218-224 (1999).
141. Passalacqua, G. et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351, 629-632 (1998).
142. Passalacqua, G. et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 104, 964-968 (1999).
143. Hawrylowicz, C. M. & O'Garra, A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nature. Rev. Immunol. 5, 271-283 (2005).
144. Lee, W. Y. & Sehon, A. H. Abrogation of reaginic antibodies with modified allergens. Nature 267, 618-619 (1977).
145. Rocklin, R. E., Sheffer, A. L., Greineder, D. K. & Melmon, K. L. Generation of antigen-specific suppressor cells during allergy desensitization. N. Engl. J. Med. 302, 1213-1219 (1980).